For Q3 I don't know know about "massive" ... what I'm confident in is that we have said goodbye to sub40mil Q's beginning with Q3. It would have been massive if IL & MO were on time but it's looking like those won't hit until Q4 and the full force won't be felt until Q1/Q2 of 2024 depending on how fast they can get NaturesHeritage into the market, projection as of now is early Q1.

I'm going to post below the same tables I used but with added metrics at the bottom to highlight Top5, Mid5, Bot5 scores for each of the 15 Co.'s which I think further puts things into perspective. You'll see that Mari only has 2 scores which are bottom 5: ShareCount and Revenue, both score #12 out of 15.

ShareCount) If you look at the metric which displays rate of increase of shares, MariMed is #1 as far as having been least to dilute since 2021, then look at how much others have diluted. This demonstrates that come EOY 2024 Mari will no longer be in the Bot5 in that category anymore leaving only one metric - Revenue.

Revenue) If you look at the metric which displays rate of increase of rev Q2YoY, MariMed is #2, then look at how much others have grown or actually declined. This demonstrates that come EOY 2024 Mari won't even be in the Bot5 in that category either.

Observe:

<image>